Ocugen, Inc.
NASDAQ:OCGNBiotechnology
+$0.03 today
- Market cap
- $250.82M
- Beta
- 2.21
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$0.22
Volume 5.83M
Average 7.51M
OCGN Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Ocugen, Inc.NASDAQ: OCGN
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash turns positive
Q1 FY2026 net change in cash was $13.29M, compared with -$20.71M a year earlier. Trailing-twelve-month net change in cash was -$5.94M. Over 3 fiscal years it compounded at +31.5% a year.
Context
- Net change in cash amounted to 904.9% of revenue in FY2025, up 427.5 pp from a year earlier.
- Net change in cash increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly net change in cash holds near $13.29M or moves back toward the trailing-twelve-month quarterly average of -$1.48M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- (39.93M) USD
- Year-over-year change
- -306.3%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (39.93M) | -306.3% |
| FY2024 | 2024-12-31 | 19.36M | +150.8% |
| FY2023 | 2023-12-31 | (38.1M) | -117.1% |
| FY2022 | 2022-12-31 | (17.55M) | -124.7% |
| FY2021 | 2021-12-31 | 70.92M | — |
Net Change in Cash vs competitors
How OCGN compares with its peers on the latest reported figures
- OCGN's LTM Mar 2026 net change in cash of $5.94M is the 8th largest of the 10 companies compared; the peer median is $8.09M.
- Its year-over-year change of -150.6% is the 8th highest of 10, against a peer median of +133.9%.
- Net change in cash amounts to 133.0% of revenue for OCGN, versus a peer median of 45.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $88.34M | +2748.7% | +2.1% | 1194.1% |
| LTM Mar 2026 | $53.39M | +167.3% | — | — | |
| LTM Mar 2026 | $36.31M | +191.7% | — | 45.9% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $19M | +133.9% | — | — |
| LTM Mar 2026 | $14.12M | -18.7% | -51.1% | — | |
| LTM Mar 2026 | $11.87M | -381.3% | -51.6% | 80.3% | |
| LTM Mar 2026 | $8.09M | +262.8% | — | — | |
| LTM Mar 2026 | $5.94M | -150.6% | +31.5% | 133.0% | |
| LTM Mar 2026 | $4.2M | +112.5% | -42.7% | 6.0% | |
| LTM Mar 2026 | $2.36M | -196.9% | — | 23.8% | |
| Peer median (excluding OCGN) | $8.09M | +133.9% | -46.9% | 45.9% | |
Competitors are the stored peer set for OCGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (58.37M) | (86.8M) | (63.08M) | (54.05M) | (67.85M) |
| Depreciation & Amortization | 229K | 480K | 704K | 1.97M | 2.39M |
| Deferred Income Tax | (52K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.96M | 10.54M | 9.22M | 7.43M | 7.71M |
| Change in Working Capital | 2.49M | 9.2M | (13.16M) | 3.67M | (523K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.5M | 0 | 0 | 0 | 0 |
| Other Working Capital | (1.01M) | 9.2M | (13.16M) | 3.67M | (523K) |
| Other Non-Cash Items | 799K | 6.51M | 4.26M | (1.15M) | 1.31M |
| Operating Cash Flow | (47.94M) | (60.08M) | (62.05M) | (42.14M) | (56.96M) |
| Capital Expenditures | (939K) | (4.46M) | (10.48M) | (3.39M) | (185K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (13.27M) | (3.95M) | 0 | 0 |
| Sales of Investments | 0 | 0 | 17.5M | 0 | 0 |
| Other Investing Activities | (877K) | 761K | 0 | 0 | (126K) |
| Investing Cash Flow | (1.82M) | (16.97M) | 3.08M | (3.39M) | (311K) |
| Debt Repayment | (10K) | 500K | 500K | 30M | (1M) |
| Common Stock Issued | 129.21M | 59.57M | 20.8M | 38.56M | 18.33M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (8.53M) | (592K) | (68K) | (3.7M) | 0 |
| Financing Cash Flow | 120.68M | 59.48M | 20.88M | 64.86M | 17.33M |
| Effect of Forex Changes | (325) | 25K | (5K) | 28K | 13K |
| Net Change in Cash | 70.92M | (17.55M) | (38.1M) | 19.36M | (39.93M) |
| Free Cash Flow | (48.88M) | (64.54M) | (72.53M) | (45.53M) | (57.15M) |
Ocugen, Inc.
NASDAQ:OCGN
Intrinsic Alpha fair value
Locked
Current Price
$0.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.